- Home
- NAKA vs KROS Comparison
NAKA vs KROS Comparison
Compare NAKA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | KROS |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | 61 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.8M | 206.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NAKA | KROS |
|---|---|---|
| Price | $3.93 | $10.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $0.75 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 360.8K | 212.9K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $1,514.38 | N/A |
| Revenue Next Year | $48.27 | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $9.69 |
| 52 Week High | $16.47 | $22.55 |
Technical Indicators
Market Signals| Indicator | NAKA | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 50.02 |
| Support Level | $0.31 | $10.64 |
| Resistance Level | $4.96 | $12.43 |
| Average True Range (ATR) | 0.42 | 0.49 |
| MACD | -0.22 | 0.09 |
| Stochastic Oscillator | 13.36 | 56.74 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.